Trials / Recruiting
RecruitingNCT07130565
Pan-Amyloid PET/CT in Various Amyloid-Related Disease
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 500 (estimated)
- Sponsor
- Tianjin Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
To evaluate the potential usefulness of 18F-92/AV45/TPZA/FT8, 11C-PIB positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various Pan-Amyloid-related disease patients.
Detailed description
Subjects with various Pan-Amyloid-related disease patients underwent 18F-92/AV45TPZA/FT8, 11C-PIB PET/CT either for an initial assessment or for recurrence detection. Lesions uptake was quantified by the maximum standard uptake value (SUVmax). The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of 18F-92/AV45TPZA/FT8, 11C-PIB PET/CT were calculated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | 18F-92/AV45/TPZA/FT8, 11CPIB | Each subject receive a single intravenous injection of 18F-92/AV45/TPZA/FT8, 11C-PIB and undergo PET/CT or MRI imaging within the specificed time. |
Timeline
- Start date
- 2023-11-01
- Primary completion
- 2028-11-01
- Completion
- 2028-11-01
- First posted
- 2025-08-19
- Last updated
- 2025-08-19
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT07130565. Inclusion in this directory is not an endorsement.